Introduction
Autotaxin was first described as a mitogenic factor expressed by a variety of tumor cells and causes mitosis and angiogenesis when added to cancer cells (Stracke, Krutzsch et al. 1992) . It was later determined that autotaxin's mitogenic activity resulted from its lysophospholipase D activity, converting lysophosphatidyl choline (LPC) to lysophosphatidic acid (LPA) (Umezu-Goto, Kishi et al. 2002) . LPA acts through activation of five G-protein coupled receptors, referred to as LPA1-5 (Ishii, Fukushima et al. 2004) , mediating changes in cell survival, proliferation and migration, tumor cell invasion, lymphocyte infiltration, angiogenesis and cytokine secretion. (Zhao, Fernandes et al. 2008) . Both autotaxin and LPA receptors have been found to be upregulated in many tumor cell lines (Kishi, Okudaira et al. 2006) and that LPA induces colony scattering (prerequisite for invasion) in several tumor cells (Shin, Kim et al. 2009) .
Recently it has been demonstrated that a pan LPA receptor antagonist reduces the size of MDA-MB-231 tumors adapted in rats (Prestwich, Gajewiak et al. 2008) The autotaxin LPA axis has been shown to be upregulated in variety of inflammatory conditions. In human rheumatoid arthritis (RA) the autotaxin gene is upregulated in fibroblasts from RA patients (Kehlen, Lauterbach et al. 2001 ) and autotaxin protein has been found in synovial fluid of patients (Nochi, Tomura et al. 2008) . LPA receptor 1 is upregulated in synovial fibroblasts from RA patients (Nochi, Tomura et al. 2008) .
Autotaxin is one of four proteins upregulated in multiple sclerosis patients as JPET # 165845 5 demonstrated by 2-D gels (Hammack, Fung et al. 2004 ). LPA1 knockout mice have been shown to be resistant to neuropathic pain produced in a spinal nerve ligation model in mice (Inoue, Rashid et al. 2004) . It has been hypothesized that LPA acts to produce pain by down regulating the mammalian K(2P)2.1 (KCNK2, TREK-1) channel (Cohen, Sagron et al. 2009 ) and Abeta-fiber-mediated spinal transmission, which underlies neuropathic pain (Xie, Matsumoto et al. 2008) .
Autotaxin is found in three main isoforms, each with a different splice variant. The most stable and common β isoform is a 95 kD protein secreted by inflammatory cells and responsible for production of LPA by the hydrolysis of LPC (produced thru sPLA2) (Giganti, Rodriguez et al. 2008) .
Autotaxin has been shown to be responsible for production of LPA in plasma. Autotaxin heterozygote knockout mice have a 50% reduction of circulating LPA as compared to wild-type (van Meeteren, Ruurs et al. 2006) . Early autotaxin inhibitors have shown that plasma LPA, generated from endogenous LPC by incubating whole blood for several hours, can be nearly 100% inhibited, suggesting that autotaxin is the primary enzyme responsible for LPA production (Ferry, Moulharat et al. 2008) . These inhibitors however were not suitable for in vivo use having limited solubility and bioavailability. One To date, there have not been autotaxin inhibitors developed which regulate LPA levels in vivo; however, there have been several reports of inhibitors that modulate autotaxin in vitro or in whole blood. Inhibitors that have been described are based on substrate analogues (Prestwich, Gajewiak et al. 2008) . These compounds are weak autotaxin inhibitors and are also LPA1 receptor agonist/antagonist. Recently, S32826 has been described as a potent inhibitor of autotaxin in vitro and in whole blood, but it's neither bioavailable nor useful for in vivo work (Ferry, Moulharat et al. 2008) .
In this paper we describe the development of an autotaxin inhibitor that modulates LPA levels in vitro and in vivo through direct inhibition of autotaxin. The compound is capable of blocking inflammation-induced LPA synthesis, both in plasma and at the site of inflammation. This will allow further testing of the hypothesis that disruption of the autotaxin/LPA axis will have beneficial anti-inflammatory effects that could impact an array of diseases such as RA, pain and cancer. The solution was then quenched with water (300 mL) and the resulting precipitate filtered.
In a separate flask (3,5-dichlorophenyl)methanol (13.0 g, 73.20 mmol was dissolved in DMF (50 ml) and sodium hydride (3.96 g, 99.0 mmol) added. The solution was stirred for 10 minutes and cooled to 0 o C. The nitro-precipitate was dissolved in DMF (50 ml) and then added dropwise to the (3,5-dichlorophenyl)methanol solution. The solution was stirred for 10 minutes and then quenched with a small amount of water to ensure quenching of excess sodium hydride. The DMF was distilled off to give a bright yellow oil which was purified by flash chromatography (5% MeOH/DCM) to give PF-8380 an off white solid (14.56 g, 30.65 mmol 42%) 1H NMR (400 MHz, 154.71, 153.98, 143.37, 141.20, 135.30, 134.03, 130.81, 127.36, 126.08, 124.97, 109.33, 108.77, 64.64, 52.83, 52.25, 43.47, 35.38 When the cell density reached 2 X 10 7 /ml, 4.5 L of fresh 293Freestlye™ media was added. The cells were transfected by the sterile addition of 640 ml of Opti-MEM® (Invitrogen, Inc.) containing 10 mg of plasmid DNA and 13 ml of 293Fectin™. The bioreactor was maintained under the initial growth conditions for another 6 days post transfection and the media was harvested for purification.
This article has not been copyedited and formatted. The final version may differ from this version. Fetal fibroblast cell assay. Human fetal fibroblast were prepared from foreskin and cultured as described (Hawley, Sullivan et al. 1980; Raz, Wyche et al. 1989 ). Cells were grown in DMEM containing 10% fetal bovine serum (FBS), 4 mM L-Glutamine, 25 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA) and Pharmacodynamic modeling. The LPA data obtained during the rat pharmacokinetic study was fit to the inhibitory E max pharmacodynamic model described by the following equation:
where the effect (E) is E max at a plasma concentration of zero (C p = 0) and E 0 as the plasma concentration approaches infinity (C p = ∞). EC 50 represents the concentration required to achieve 50% of the maximal inhibitory effect. Pharmacodynamic modeling was conducted using all plasma concentration and respective LPA concentration data with WinNonlin version 5.2 (Pharsight, Mountain View, CA). Pharmacokinetics. The pharmacokinetic profile of PF -8380 was evaluated at an IV dose of 1 mg/kg and oral doses of 1 to 100 mg/kg out to 24 hours (Figure 2A & B) . PF-8380 has mean clearance of 31 mL/min/kg, volume of distribution at steady state of 3.2 L/kg, and effective t 1/2 of 1.2 hours (Table 2 ). Oral bioavailability is moderate ranging JPET # 165845 18 from 43 to 83% (Table 2) . Plasma concentrations increase with single oral escalating doses ( Figure 2B) but Cmax increases at a rate that is approximately proportional to dose from 1 to 10 mg/kg and less than proportional to dose from 10 to 100 mg/kg ( Figure 2C ).
Sample Preparation and LC-MS/MS Analysis of
PF-8380 exposures estimated by area under the curve are approximately proportional to dose and linear up to 100 mg/kg ( Figure 2C ). Plasma C16:0, C18:0 and C20:0 LPA levels were measured immediately following collection ( Figure 2D shows C18:0 LPA levels at all doses). Maximal reduction of LPA levels were observed by the 3 mg/kg dose at 0.5 hours with all LPA returning at or above baseline at 24 hours.
PF-8380 Pharmacodynamics. The pharmacodynamic effect of PF-8380 was measured as decreasing C16:0, C18:0 and C20:0 LPA levels in the plasma. The plasma LPA levels and PF-8380 concentrations were fit to an inhibitory E max model and the model parameters (EC 50 , E max , and E 0 ) for each LPA are presented in Table 3 . The effect of PF-8380 on plasma LPA levels indicates a direct response (Supplementary data Figure 1-4) .
Data show that LPA concentrations decline rapidly and reaches it's maximal inhibition between 15 and 30 minutes post administration for all doses levels, corresponding with PF-8380 plasma t max (Table 2) . It is interesting to note that the EC 50 values obtained (means = 51.7 -84.6 nM) are similar to the IC 50 value obtained from human whole blood in the in vitro potency assay (Table 1) .
In vivo modulation of LPA levels. Reduction of LPA in vivo, both in plasma and at the site of inflammation was evaluated in a rat air pouch model of inflammation. PF-8380 was dosed orally and provided dose proportional blood levels from 0.079 at 3 mg/kg to This article has not been copyedited and formatted. The final version may differ from this version. Since most preclinical animal models are done in rodents, the potency of PF-8380 was evaluated against rat autotaxin. Rat and murine autotaxin sequences are identical, so these measurements can be used for either species. The potency in the recombinant enzyme assay were comparable to human. A determination was made that human whole blood assays could be used to estimate potency in a rodent system. Human whole blood potency was shifted as expected to the right, probably due to protein binding. PF-8380 inhibited plasma autotaxin activity > 90% indicating that it is the major source of LPA production in plasma.
Analysis of a pharmacokinetic/pharmacodynamic (PK/PD) relationship was attempted by measuring plasma LPA. Our initial observations with human whole blood and the observation in autotaxin heterozygote knockout animals indicate that autotaxin is the major source of LPA in plasma. In order to determine a PK/PD effect however, the rate of biosynthesis/degredation of LPA needs to be taken into account. Whole blood assays depend on an incubation period from several up to 24 hours to produce LPA from plasma autotaxin activity. The analysis done in this paper was careful to limit the time of incubation of the plasma post sampling, but with many time points it was difficult to obtain samples at precisely the right time, meaning that there was most certainly some incubation time. In any event, LPA levels were rapidly reduced following oral dosing, indicating that LPA present at basal levels in the plasma is rapidly degraded.
Analysis of the in vivo effects of PF-8380 on production of LPA in plasma and in the inflamed air pouch indicates a close correlation between plasma, pouch and ex vivo whole blood inhibition of autotaxin activity. Plasma and pouch samples were collected immediately and processed for LPA analysis. Plasma samples without incubation to determine autotaxin activity did not show a dose dependent decrease in LPA as was seen in the PK study. Plasma that was incubated for 4 hours at RT showed a very good dose response. This indicated that basal LPA levels are not as sensitive to autotaxin inhibition and that analysis of autotaxin activity needs to be performed to determine a PK/PD relationship. Pouch samples on the other hand, either with 4 hours of incubation or no incubation, both showed a similar dose response. Presumably the pouch , with a robust inflammatory condition produces much more autotaxin, hence higher basal levels of LPA and is sensitive to autotaxin inhibition.
In order to estimate doses necessary to inhibit LPA formation in vivo at the site of inflammation, a correlation of human whole blood inhibition of plasma autotaxin activity and air pouch autotaxin activity indicate that there is a close correlation of the three. This suggests that a whole blood assay can be an accurate measure of subsequent doses needed to completely inhibit the production of LPA at the site of inflammation. Autotaxin's role JPET # 165845 23 in the production of LPA at the site of inflammation was then tested with PF-8380.
Immediately after samples were taken from the pouch LPA levels were analyzed, this minimized LPA formation by autotaxin activity in the fluid. LPA levels in the pouch were inhibited >90% indicating that autotaxin is the primary source of LPA at the site of inflammation. PF-8380 was evaluated for its inhibition of inflammatory hyperalgesia in rat adjuvant induced arthritis. Maximal efficacy in hyperalgesia was equal to naproxen at 30 mg/kg. In previous studies, naproxen dosed orally at 10 mg/kg that was determined from biomarker data to be efficacious to inhibit PGE2 thus both forms of cyclooxygenase.
A dose of naproxen 3 times higher was used in this study, which represents maximal effect based on cyclooxygenase. Naproxen at 100 mg/kg produces side effects in rats such as GI side effect that will not provide mechanism-based data and therefore we did not test higher doses than 30 mg/kg. This indicated that hyperalgesia caused by adjuvant induced arthritis is primarily peripheral, since the LPA biomarkers in this study were peripheral measures of LPA reduction.
In summary, this is the first report of an inhibitor of autotaxin that reduces LPA levels in vivo. PF-8380 has been demonstrated to be a potent inhibitor of autotaxin in vitro using native enzyme and substrate and also in ex vivo human whole blood. PF-8380 is bioavailable and can be dosed in vivo to levels that are several multiples above the ED80, which can be accomplished with twice a day dosing at 10 mg/kg. Autotaxin's role in the production of LPA at the site of inflammation was confirmed in the rat air pouch model of inflammation. Autotaxin was inhibited > 90% both in plasma and at the site of inflammation by PF-8380, indicating that autotaxin is the primary enzyme responsible for JPET # 165845 24 the production of LPA at the site of inflammation. Measurement of autotaxin activity in ex vivo whole blood or plasma can be used to calculate dose projections and PF-8380 can now be used as a pharmacological tool to evaluate the role that LPA plays in inflammation and cancer.
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